Bivalirudin dosage in published studies and labels

These are the doses used for Bivalirudin in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.

Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.

Last checked against primary sources: November 7, 2026

Studied regimens and sources

Bivalirudin has an FDA-approved human dosage as an intravenous anticoagulant for adults undergoing percutaneous coronary intervention (PCI), including people with heparin-induced thrombocytopenia. The label's recommended dose is a 0.75 mg/kg intravenous bolus followed immediately by an infusion of 1.75 mg/kg per hour for the duration of the procedure, given with aspirin.

FDA Approved

Dosage evidence summary for Bivalirudin
Human dosing established	Yes
Route	Intravenous
Frequency	Intravenous bolus followed by continuous infusion
Duration studied	For the duration of the procedure; up to 4 hours afterwards may be considered in STEMI
Half-life	About 25 minutes with normal kidney function; longer with kidney impairment (3.5 hours in dialysis patients)
Evidence level	FDA Approved
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Bivalirudin, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
FDA label — anticoagulation during percutaneous coronary interventionFDA-approved label · FDA prescribing information	Adults undergoing PCI, including those with heparin-induced thrombocytopenia (HIT/HITTS), receiving aspirin	0.75 mg/kg bolus, then 1.75 mg/kg/hour; an extra 0.3 mg/kg bolus if the activated clotting time 5 minutes later calls for it	Intravenous	Bolus, then continuous infusion	For the procedure; extending the infusion up to 4 hours after PCI should be considered in STEMI	Anticoagulation during PCI	Bivalirudin for injection (Sandoz, NDA 020873) — FDA prescribing information, DailyMed
FDA label — kidney impairmentFDA-approved label · FDA prescribing information	Adults undergoing PCI with creatinine clearance below 30 mL/min, or on hemodialysis	Same bolus; infusion reduced to 1 mg/kg/hour (creatinine clearance below 30 mL/min) or 0.25 mg/kg/hour (hemodialysis)	Intravenous	Bolus, then continuous infusion	For the procedure	Dose adjustment with anticoagulant monitoring	Bivalirudin for injection (Sandoz, NDA 020873) — FDA prescribing information, DailyMed

Where sources disagree

Bivalirudin is a direct thrombin inhibitor used during PCI. The label warns that it increases the risk of bleeding, that acute stent thrombosis was more frequent in STEMI patients undergoing primary PCI, and that thrombus formation, including fatal cases, was more likely during gamma brachytherapy. There is no known antidote.
Overdoses reported in trials and after marketing were often due to not reducing the infusion in people with kidney impairment, according to the label. Safety and effectiveness in children have not been established.
The label describes a 250 mg vial that is reconstituted and then diluted before intravenous use.